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OBJECTIVE—In part, activation of invariant natural killer T
(iNKT)-cells with the superagonist -galactosylceramide (-Gal-
Cer) inhibits the development of T-cell–mediated autoimmune
type 1 diabetes in NOD mice by inducing the downstream
differentiation of antigen-presenting dendritic cells (DCs) to an
immunotolerogenic state. However, in other systems iNKT-cell
activation has an adjuvant-like effect that enhances rather than
suppresses various immunological responses. Thus, we tested
whether in some circumstances genetic variation would enable
activated iNKT-cells to support rather than inhibit type 1 diabetes
development.
RESEARCH DESIGN AND METHODS—We tested whether
iNKT-conditioned DCs in NOD mice and a major histocompati-
bility complex–matched C57BL/6 (B6) background congenic
stock differed in capacity to inhibit type 1 diabetes induced by
the adoptive transfer of pathogenic AI4 CD8 T-cells.
RESULTS—Unlike those of NOD origin, iNKT-conditioned DCs
in the B6 background stock matured to a state that actually
supported rather than inhibited AI4 T-cell–induced type 1 diabe-
tes. The induction of a differing activity pattern of T-cell costimu-
latory molecules varying in capacity to override programmed
death-ligand-1 inhibitory effects contributes to the respective
ability of iNKT-conditioned DCs in NOD and B6 background mice
to inhibit or support type 1 diabetes development. Genetic
differences inherent to both iNKT-cells and DCs contribute to
their varying interactions in NOD and B6.H2
g7 mice.
CONCLUSIONS—This great variability in the interactions be-
tween iNKT-cells and DCs in two inbred mouse strains should
raise a cautionary note about considering manipulation of this
axis as a potential type 1 diabetes prevention therapy in geneti-
cally heterogeneous humans. Diabetes 59:423–432, 2010
I
nvariant natural killer T (iNKT)-cells are a small
regulatory lymphocyte subset characterized by their
unique ability to recognize glycolipid antigens pre-
sented by the major histocompatibility complex
(MHC) class I–like CD1d molecule (1). Activated iNKT-
cells induce profound multiple effects on innate and
adaptive immune responses, primarily through rapid se-
cretion of various cytokines and other agents (1,2). Among
the downstream events regulated by activated iNKT-cells
is the maturation of dendritic cells (DCs) that subse-
quently induce various adaptive immune responses (1).
Activating iNKT-cells with various agonists has shown
promise in modulating DC functions for both stimulating
immunological responses against tumors and infectious
agents as well as inducing tolerogenic responses for
inhibiting autoimmune syndromes (1,3,4). Unfortunately,
in regard to possible iNKT-mediated therapeutic ap-
proaches in humans, too little is currently known about
how iNKT-cells promote differentiation of immunogenic
versus tolerogenic DCs. Without an ability to regulate
desired downstream DC responses, the danger exists of
iNKT-directed protocols exacerbating the disease being
treated (3,4). Therefore, much attention is currently fo-
cused on characterizing particular courses of iNKT-cell–
induced DC differentiation.
Mouse-based studies assessing the ability of iNKT-cells
activated by the superagonist -galactosylceramide (-
GalCer) to enhance antitumor immunity have almost ex-
clusively used the C57BL/6J (B6) or BALB/c strains (5–10).
More strains have been evaluated for -GalCer–induced
suppression of various autoimmune syndromes (4).
Hence, strain-dependent factors may be important in
determining whether activated iNKT-cells induce immu-
nogenic or tolerogenic events. Indeed, there is great
strain variability in iNKT-cell numbers that also differ in
cytokine production proﬁles (11). However, it remains
unknown to what extent genetic variability may deter-
mine whether activated iNKT-cells subsequently induce
immunogenic versus tolerogenic differentiation of DCs.
The ability of -GalCer–activated iNKT-cells to inhibit
autoimmune type 1 diabetes development in NOD mice
may be at least partly due to downstream maturation of
tolerogenic DCs (2). iNKT-conditioned DCs in NOD mice
preferentially accumulated in pancreatic lymph nodes
where some diabetogenic T-cells subsequently underwent
apoptotic deletion, but with a larger proportion becoming
functionally anergized (2). However, before -GalCer–
based type 1 diabetes intervention approaches could be
considered in humans, it would be important to know
whether patient genetic heterogeneity may result in
variable types of downstream DC responses. Indeed, in
the current study, we found that unlike in NOD mice,
in a B6 background stock iNKT-conditioned DCs not
only failed to mature to a type 1 diabetes–protective
state, but actually support disease development due to
differing expression of various T-cell costimulatory and
inhibitory molecules.
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Mice. NOD/ShiLtDvs mice are maintained by sibling matings in a speciﬁc
pathogen-free research colony at The Jackson Laboratory. B6 mice congenic
for the NOD-derived H2
g7 MHC (B6.H2
g7) are maintained at the N8 backcross
generation (12). N12 backcross generation NOD mice congenic for a disrupted
CD1d gene (NOD.CD1d
null) have been described (13). NOD mice transgeni-
cally expressing the T-cell receptor (TCR) from the diabetogenic AI4 CD8

T-cell clone and also carrying a functionally inactivated Rag1 gene
(NOD.Rag1
null.AI4) have been described (14).
Flow cytometric analyses and reagents. -GalCer was purchased from
Alexis Biochemicals (San Diego, CA). Splenic DCs from NOD and B6.H2
g7
mice treated 24 h previously with a single intraperitoneal injection of -GalCer
(2 g) or vehicle (DMSO) were characterized by ﬂow cytometry. Cell
suspensions were Fc receptor blocked with rat (r)IgG and stained with the
indicated ﬂuorochrome-conjugated antibodies at 4°C. DCs were identiﬁed
using a CD11c-speciﬁc antibody (N148). Expression levels of various DC
surface markers were assessed using antibodies speciﬁc for CD80 (16-10AI),
CD86 (GL1), CD70 (FR70), CD40 (3/23), pan-MHC I (M1/42), A
g7-MHC II
(10-2.16), programmed death-ligand-1 (PD-L1; MIH6), and OX40 ligand
(OX40L; RM134L), all purchased from BD Biosciences (San Jose, CA) or
eBiosciences (San Diego, CA). In mixed splenocyte studies, anti-CD45.2
(1042.1) was used to distinguish B6.H2
g7 DCs from those of NOD origin.
Viable stained cells were detected using LSR II or FACSCalibur ﬂow cytom-
eters (BD Biosciences). Data were analyzed using FlowJo software (TreeStar,
Palo Alto, CA).
Adoptive transfer of DCs and type 1 diabetes. DCs were puriﬁed from
Collagenase D (Roche) digested spleens of female NOD or B6.H2
g7 mice
injected intraperitoneally 24 h previously with -GalCer (2 g) or DMSO using
CD11c-conjugated magnetic beads following the manufacturer’s directions
(Miltenyi Biotec). Between 1  10
5 and 4  10
5 CD11c
 DCs were injected
intravenously into sublethally irradiated (600 R from a
137Cs source) 6- to
8-week-old syngeneic NOD or B6.H2
g7 female recipients. DC recipients were
injected intravenously 24 h later with 1  10
7 NOD.Rag1
null.AI4 splenocytes
to induce type 1 diabetes. Type 1 diabetes onset in recipient mice was deﬁned
by glycosuria development assessed daily with Ames Diastix (Bayer, Diagnos-
tics Division).
In some experiments, 6- to 8-week-old NOD and B6.H2
g7 females received
a single intraperitoneal injection of -GalCer (2 g) or vehicle, and 18 h later
were sublethally irradiated and infused intravenously with 1  10
7
NOD.Rag1
null.AI4 splenocytes. Another experiment used NOD and B6.H2
g7
females receiving four once-weekly intraperitoneal injections of -GalCer (2
g) or vehicle starting at 3–4 weeks of age. Two days after the last treatment,
mice were sublethally irradiated and injected intravenously with 1  10
7
NOD.Rag1
null.AI4 splenocytes. Recipients received an additional -GalCer or
vehicle injection 5 days after AI4 T-cell transfer and were monitored for type
1 diabetes. In some experiments, recipients were given additional intraperi-
toneal injections of the PD-L1–blocking MIH6 antibody (250 g/mouse) or
polyclonal rat IgG, at the same time as and 2 days after AI4 T-cell transfer.
T-cell proliferation and IFN enzyme-linked immunosorbent spot
assays. Splenic DCs puriﬁed from 6- to 8-week-old male NOD and B6.H2
g7
mice injected 24 h previously with either -GalCer or DMSO and ﬁxed in 0.75%
paraformaldehyde (15) to prevent further maturation were assessed for ability
to activate magnetic bead–puriﬁed AI4 T-cell responses to the YFIENYLEL
mimotope peptide using both the previously described enzyme-linked immu-
nosorbent spot IFN production (16) and [
3H]thymidine incorporation prolif-
eration assays (12).
Dendritic cell cytokine analysis. Splenic DCs were puriﬁed as described
above from male 6- to 8-week-old NOD or B6.H2
g7 mice injected intraperito-
neally 16 h previously with -GalCer (2 g) or DMSO. DCs were cultured at a
concentration of 5  10
5/ml in tissue culture media for an additional 18 h with
or without the addition of anti-CD40 (clone HM40-3; 10 g/ml) and lipopoly-
saccharide (LPS; 1 g/ml), after which supernatants were collected for
interleukin-12 (IL-12) p70, tumor necrosis factor-, and IL-10 cytokine detec-
tion via ELISA kits (BD Biosciences).
PD-L1– and CD70-blocking assays. Splenic DCs were puriﬁed and ﬁxed as
described above from NOD and B6.H2
g7 mice treated with -GalCer (2 g)
and either PD-L1–blocking antibody (clone 10F.9G2; 400 g/mouse) or an
equivalent amount of rIgG 24 h and 16 h previously. A subset of ﬁxed DCs was
assessed for the extent of PD-L1 blockade by staining with ﬂuorochrome-
conjugated MIH6 antibody. For the CD70-blocking experiment, anti-CD70 or
rIgG (10 g/ml) was added to tissue culture media containing splenic DCs
puriﬁed and ﬁxed from NOD and B6.H2
g7 mice treated with -GalCer 24 h
previously. In both blocking experiments, treated iNKT-conditioned DCs
(2.5  10
4 per well) were used to induce antigenic mimotope-mediated (6.25
and 12.5 nmol/l for the CD70- and PD-L1–blocking experiments, respectively)
proliferation of puriﬁed carboxyﬂuorescein succinimidyl ester (CFSE)–la-
beled NOD.Rag1
null.AI4 T-cells (5  10
4 per well). After 3 days, AI4 T-cell
proliferation was assessed by ﬂow cytometric analyses of CFSE dilution.
Cell culture. For the mixed splenocyte culture, a 1:1 ratio of NOD and
B6.H2
g7 splenocytes was seeded at a concentration of 5  10
6/ml in RPMI
1640 with or without -GalCer (200 ng/ml) and cultured at 37°C for 2 days.
Cells were harvested and stained with ﬂuorochrome-conjugated antibodies to
CD11c and CD45.2 as well as CD86 or PD-L1 for ﬂow cytometric analyses.
Another experiment involved coculture of puriﬁed iNKT-cells and DCs.
Splenic DCs were puriﬁed to 90% purity from 6- to 8-week-old female NOD
and B6.H2
g7 mice as described above. iNKT-cells were isolated from spleno-
cytes by staining with a phycoerythrin-conjugated CD1d tetramer loaded with
the -GalCer PBS57 analog provided by the National Institutes of Health
Tetramer Facility. iNKT-cells were enriched to 70% purity by positive
selection using an MS Column (Miltenyi Biotec). NOD or B6.H2
g7 DCs (1  10
5
cells/well) were cocultured with syngeneic or allogeneic iNKT-cells (1.5  10
4
per well) in round-bottomed 96-well tissue culture plates in the presence of
vehicle or -GalCer (200 ng/ml) for 18 h. Cells were then harvested and stained
with ﬂuorochrome-conjugated antibodies to CD11c, CD86, and PD-L1 for ﬂow
cytometric analyses.
RESULTS
iNKT-conditioned NOD DCs prevent type 1 diabetes.
Although their presence has been associated with the
induction of type 1 diabetes resistance, it remained un-
clear whether iNKT-conditioned DCs in NOD mice directly
trigger disease-protective effects. Thus, we determined
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FIG. 1. DCs from -GalCer–treated NOD donor mice protect NOD and iNKT-cell–deﬁcient NOD.CD1d
null recipients from type 1 diabetes induced
by adoptively transferred AI4 T-cells. Type 1 diabetes incidence for sublethally irradiated (600R) 6- to 8-week-old (A) NOD and (B) NOD.CD1d
null
recipients of 1–4  10
5 splenic DCs isolated from NOD donors treated 24 h previously with -GalCer (2 g) or DMSO. NOD.Rag1
null.AI4
splenocytes (1  10
7) were injected into all DC recipients 24 h later. Survival curves were compared according to the log-rank test.
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Cer or vehicle 24 h previously and adoptively transferred into
young (6–8 weeks old) syngeneic recipients differed in
ability to protect them from type 1 diabetes normally induced
by subsequently infused NOD.Rag1
null.AI4 TCR transgenic
CD8 T-cells (due to the Rag1
null mutation all donor T-cells
are the AI4 clonotype) (2). AI4 T-cells induced a signiﬁ-
cantly lower and slower rate of type 1 diabetes in NOD
mice previously infused with DCs from -GalCer than
vehicle-pretreated donors (Fig. 1A). A concern was
whether type 1 diabetes protection mediated by DCs from
-GalCer–treated donors actually resulted from their car-
rying over some amount of this glycolipid antigen eliciting
a second round of iNKT-cell activation in recipient mice,
triggering a non–DC-mediated mode of disease resistance.
We addressed this issue by repeating the DC transfer
experiment, but using NOD.CD1d
null recipients lacking
iNKT-cells (17). Again, AI4 T-cells induced a signiﬁcantly
lower rate of type 1 diabetes in NOD.CD1d
null recipients
previously infused with DCs from -GalCer than vehicle-
pretreated NOD donors (Fig. 1B). Hence, adoptively trans-
ferred iNKT-conditioned DCs do not elicit type 1 diabetes
resistance by reactivating recipient iNKT-cells. These col-
lective data indicate iNKT-conditioned DCs in NOD mice
mature to a state capable of inhibiting diabetogenic
T-cells.
iNKT-conditioned DCs from B6.H2
g7 mice support
type 1 diabetes development. We next asked whether
iNKT-conditioned DCs still suppress diabetogenic T-cell
responses if derived from a strain such as B6 in which
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FIG. 2. Unlike those of NOD origin, iNKT-conditioned B6.H2
g7 DCs functionally support diabetogenic T-cell activation. A: Type 1 diabetes
incidence for sublethally irradiated 6- to 8-week-old female B6.H2
g7 recipients of 2  10
5 splenic DCs isolated from syngeneic donors treated 24 h
previously with -GalCer (2 g) or vehicle. NOD.Rag1
null.AI4 splenocytes (1  10
7) were injected into all DC recipients 24 h later. B and C: Type
1 diabetes incidence for (B) B6.H2
g7 and (C) NOD recipients pretreated with a single intraperitoneal injection of -GalCer (2 g) or vehicle
followed 18 h later by sublethal irradiation (600 R) and intravenous infusion of 1  10
7 NOD.Rag1
null.AI4 splenocytes. D and E: Type 1 diabetes
incidence for (D) B6.H2
g7 and (E) NOD recipients pretreated from 3–4 weeks of age with four once-weekly injections of -GalCer (2 g) or
vehicle followed by sublethal irradiation (600 R) and intravenous infusion of 1  10
7 NOD.Rag1
null.AI4 splenocytes. Recipients received an
additional dose of -GalCer or vehicle 5 days later. Survival curves in (A–E) were compared according to the log-rank test.
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rather than diminishing immunological effector functions
(5–10). B6 background mice congenically expressing the
NOD H2
g7 MHC (B6.H2
g7) are inherently type 1 diabetes
resistant, but susceptible to AI4 T-cell–induced disease
(18). Thus, we assessed whether splenic DCs puriﬁed from
B6.H2
g7 donors treated 24 h previously with -GalCer or
vehicle differed from those of NOD origin in ability to
protect syngeneic recipients from AI4 T-cell–induced type
1 diabetes. Unlike those of NOD origin (Fig. 1A), iNKT-
conditioned DCs from B6.H2
g7 mice actually accelerated
AI4 T-cell–induced type 1 diabetes in syngeneic recipients
(Fig. 2A). Similarly, type 1 diabetes was, respectively,
accelerated and inhibited in B6.H2
g7 and NOD mice
receiving a single intraperitoneal injection of -GalCer
18 h prior to AI4 T-cell infusion (Fig. 2B and C). These
results indicate that after single-dose -GalCer treatment,
iNKT-conditioned DCs in NOD and B6.H2
g7 mice differen-
tiate to tolerogenic versus immunogenic states, respectively,
either inhibiting or supporting AI4 T-cell–induced type 1
diabetes. However, it has been reported that B6 background
mice must receive a minimum of three consecutive -GalCer
injections for iNKT-cells to achieve a maturation state
supporting the generation of tolerogenic DCs that inhibit
development of experimental allergic encephalomyelitis
(19). Similarly, NOD mice pretreated with four once-
weekly injections of -GalCer are rendered resistant to AI4
T-cell–induced type 1 diabetes (2). Thus, we tested
whether four once-weekly pretreatments with -GalCer
also protected B6.H2
g7 mice from subsequent AI4 T-cell–
induced type 1 diabetes. Unlike in NOD, multiple pretreat-
ments with -GalCer failed to protect B6.H2
g7 mice from
AI4 T-cell–induced type 1 diabetes (Fig. 2D and E). Hence,
even after multiple -GalCer injections, iNKT-conditioned
DCs from NOD and B6.H2
g7 inhibit or support, respec-
tively, type 1 diabetes development. Furthermore, these
collective results suggest the experimental allergic en-
cephalomyelitis–protective DCs engendered in B6 mice
pretreated with multiple -GalCer injections must func-
tionally do so in a way differing from those maturing to a
type 1 diabetes inhibitory state in NOD mice after only a
single round of iNKT-cell activation. -GalCer–activated
iNKT-cells reportedly inhibit type 1 diabetes in NOD mice
in a regulatory T-cell (Treg)—dependent manner (20).
However, we could not detect any proportional or func-
tional differences in Tregs from NOD or B6.H2
g7 mice
pretreated with single or multiple injections of -GalCer
(data not shown). Hence, we assessed whether iNKT-
conditioned DCs from NOD and B6.H2
g7 mice differed in
ability to activate AI4 T-cell effector function. DCs were
puriﬁed from NOD and B6.H2
g7 mice treated with -Gal-
Cer or vehicle 24 h earlier and ﬁxed in 0.75% paraformal-
dehyde to prevent further maturation in culture (15). They
were then used to induce antigenic mimotope-mediated
activation and proliferation of NOD.Rag1
null.AI4 T-cells.
Compared with those from vehicle-treated syngeneic con-
trols, iNKT-conditioned DCs from B6.H2
g7 mice drove
higher levels of antigen-stimulated AI4 T-cell proliferation
and IFN production (Fig. 3A and B). Conversely, com-
pared with those from vehicle-treated syngeneic controls,
iNKT-conditioned DCs from NOD mice did not demon-
strate an enhanced ability to support AI4 T-cell prolifera-
tion and only marginally increased their IFN production
(Fig. 3A and B). Hence, iNKT-conditioned NOD and
B6.H2
g7 DCs differentiate to very different states charac-
terized by a low or potent ability, respectively, to activate
diabetogenic AI4 T-cells. These results would also be
consistent with our previous ﬁndings (2) that although
there is an increase in the number of AI4 T-cells that
undergo apoptotic deletion in -GalCer–treated NOD
mice, a larger proportion of such effectors is driven to an
anergic state.
iNKT-conditioned NOD and B6.H2
g7 DCs express
different patterns of costimulatory molecules. The
capacity of DCs to stimulate T-cells is the net result of
MHC and costimulatory molecule as well as proinﬂam-
matory and anti-inﬂammatory cytokine interactions. To
determine possible cytokine contributions, iNKT-condi-
tioned DCs were puriﬁed from NOD and B6.H2
g7 mice 16 h
after -GalCer treatment and cultured for a further 18 h
with or without a combination of anti-CD40 and LPS.
Supernatants were then assessed for various cytokine
levels by enzyme-linked immunosorbent assay. After acti-
vation, iNKT-conditioned DCs from B6.H2
g7 mice pro-
duced higher levels of IL-12 p70 and tumor necrosis
factor- and lower quantities of IL-10 than those of NOD
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FIG. 3. iNKT-conditioned DCs from NOD and B6.H2
g7 mice differ in ability to activate AI4 T-cell effector function. A and B: DCs were puriﬁed from
NOD and B6.H2
g7 mice treated 24 h previously with -GalCer or vehicle and lightly ﬁxed in 0.75% paraformaldehyde to prevent further
maturation. DCs (2  10
4 per well) were then used to induce antigenic mimotope-mediated (A) proliferation and (B) IFN production by puriﬁed
NOD.Rag1
null.AI4 T-cells. Results represent the mean cpm and IFN spots per 5  10
4 AI4 T-cells  SE of three mice per treatment. *P < 0.001
as determined by one-way ANOVA. Boxed values in (B) indicate the fold change in IFN production by NOD.Rag1
null.AI4 T-cells activated by DCs
puriﬁed from -GalCer– compared with vehicle-treated mice.
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dix at http://diabetes.diabetesjournals.org/content/early/
2009/10/31/db09-1116/suppl/DC1). However, although they
may contribute to some extent in vivo, it is unlikely that
these cytokines are primary factors in the varying ability of
NOD and B6.H2
g7 iNKT-conditioned DCs to activate dia-
betogenic T-cells. This is because, unless further activated
with anti-CD40 and LPS, neither strain’s iNKT-conditioned
DCs produced detectable amounts of the aforementioned
cytokines. Furthermore, the ﬁxed NOD and B6.H2
g7 DCs
found in the previously described in vitro assays (Figs. 2
and 3) to vary in ability to activate diabetogenic AI4 T-cells
would lack cytokine production capacity. For these rea-
sons, attention was focused on the possibility that varying
expression levels of important T-cell costimulatory and
inhibitory molecules are responsible for the divergent
effects of NOD and B6.H2
g7 iNKT-conditioned DCs on
diabetogenic AI4 T-cells.
As determined by assessing the mean ﬂuorescence
intensity (MFI) of speciﬁc antibody binding, at 24 h after
-GalCer treatment, levels of MHC class I and II as well as
CD80 and CD86 expression were signiﬁcantly higher on
iNKT-conditioned DCs from B6.H2
g7 than NOD mice (Fig.
4). Surface CD70 and OX40L levels are upregulated on
activated DCs and play important roles in initiating and
sustaining T-cell activation through respective interactions
with the CD27 and OX40 lymphocyte receptors (22–24).
After iNKT-cell activation, expression of both CD70 and
OX40L was completely unaltered on NOD but upregulated
signiﬁcantly on B6.H2
g7 DCs (Fig. 4).
CD40 engagement by T-cell–expressed CD40 ligand
reportedly contributes to DCs subsequently upregulating
expression of CD80 and CD86 costimulatory molecules
(25,26). Again, CD40 expression was signiﬁcantly higher
on iNKT-conditioned DCs from B6.H2
g7 than NOD mice
(Fig. 4). However, this CD40 disparity could not explain
strain differences in expression of other T-cell costimula-
tory molecules on iNKT-conditioned DCs. This was dem-
onstrated by the ﬁnding that iNKT-conditioned DCs from
CD40-deﬁcient B6 mice still efﬁciently upregulated expres-
sion of other T-cell costimulatory molecules (data not
shown).
Levels of the important T-cell–inhibitory PD-L1 mole-
cule on iNKT-conditioned DCs from NOD and B6.H2
g7
mice were also compared. PD-L1 can be expressed on
mature DCs and inhibits activated T- and B-cells when
engaging PD-1 (27,28). This interaction regulates type 1
diabetes in NOD mice as antibody blockade of either the
ligand or receptor accelerates disease onset by inhibiting
apoptosis of pathogenic lymphocytes (29). PD-L1 was
upregulated on iNKT-conditioned DCs in both strains, but
again a more robust response was observed in B6.H2
g7
mice (Fig. 4). However, based on these collective results,
we hypothesized that the induction of differing activity
patterns of T-cell costimulatory molecules varying in ca-
pacity to override PD-L1 inhibitory effects contributes to
the respective ability of iNKT-conditioned DCs from NOD
and B6.H2
g7 mice to inhibit or support type 1 diabetes
development.
Tolerogenic and immunogenic properties of NOD and
B6.H2
g7 iNKT-conditioned DCs are abrogated by re-
spective treatment with PD-L1– or CD70-blocking
antibodies. The T-cell costimulatory molecule we initially
chose to test the above hypothesis was CD70 because its
expression is unchanged or strongly upregulated on iNKT-
conditioned DCs in NOD and B6.H2
g7 mice, respectively
(Fig. 4). Hence, we determined whether either PD-L1 or
CD70 blockade altered the ability of iNKT-conditioned
DCs from NOD or B6.H2
g7 mice to stimulate AI4 T-cells. In
one experiment, DCs were puriﬁed from NOD and B6.H2
g7
mice treated with -GalCer and either a PD-L1–blocking
antibody or polyclonal rIgG 24 h and 16 h previously and
then ﬁxed in 0.75% paraformaldehyde to prevent further
maturation in culture (15). PD-L1 blockade was conﬁrmed
on DCs directly after ﬁxation (supplementary Fig. 2). DCs
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FIG. 4. iNKT-cell–conditioned DCs from NOD and B6.H2
g7 mice ex-
press different patterns of T-cell costimulatory and inhibitory mole-
cules. Flow cytometry was used to determine the mean ﬂuorescence
intensity (MFI) of antibody staining of T-cell costimulatory and inhib-
itory molecules on the surface of naive and iNKT-matured CD11c
 DCs
resident within splenocytes of 6- to 8-week-old female NOD and
B6.H2
g7 mice (n  3) injected intraperitoneally 24 h previously with
-GalCer (2 g) or DMSO. Boxed values indicate the within-strain fold
change in expression levels of the indicated surface molecule on
splenic DCs from -GalCer– compared with DMSO-treated mice. Dif-
ferences across strains in absolute expression levels of surface mole-
cules and the fold change induction within strains above baseline
between iNKT-conditioned DCs from NOD and B6.H2
g7 mice were
compared by one-way ANOVA.
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g7 mice
treated 24 h previously with -GalCer and placed in
culture together with rIgG or CD70-blocking antibody (the
CD70 antibody showed very poor binding persistence in
vivo). DCs from each treatment group were used to induce
antigenic peptide–mediated proliferation of CFSE-labeled
AI4 T-cells.
As previously observed, PD-L1 intact iNKT-conditioned
DCs from rIgG-treated NOD mice did not efﬁciently sup-
port AI4 T-cell proliferation (Fig. 5A). Conversely, AI4
T-cells proliferated vigorously when PD-L1–blocked iNKT-
conditioned DCs from NOD mice were used for antigen
presentation. Unlike NOD, PD-L1 intact iNKT-conditioned
DCs from B6.H2
g7 mice promoted robust AI4 T-cell acti-
vation. Furthermore, PD-L1 blockade of iNKT-conditioned
B6.H2
g7 DCs only marginally increased their AI4 T-cell
stimulatory capacity (Fig. 5A).
The greater ability of rIgG control-treated iNKT-condi-
tioned DCs from B6.H2
g7 than NOD mice to activate AI4
T-cells correlated with their CD70 expression levels (Fig.
5B). However, addition of the CD70-blocking antibody
completely abrogated the ability of iNKT-conditioned DCs
from either strain to induce antigen-mediated AI4 T-cell
proliferation (Fig. 5B).
These collective data indicate AI4 T-cell activation is
sensitive and insensitive to inhibition by PD-L1 signaling
from NOD and B6.H2
g7 iNKT-conditioned DCs, respec-
tively. This variability is likely due to much higher levels of
costimulatory molecules, including CD70, provided to AI4
T-cells by iNKT-conditioned DCs from B6.H2
g7 than NOD
mice.
PD-L1 blockade inhibits the ability of NOD but not
B6.H2
g7-activated iNKT-cells to mediate type 1
diabetes–protective effects. Given the above results, we
hypothesized in vivo PD-L1 blockade would abrogate the
earlier described ability of -GalCer–activated iNKT-cells to
inhibit AI4 T-cell–induced type 1 diabetes in NOD but not
B6.H2
g7 mice. To test this hypothesis, NOD.Rag1
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FIG. 5. The tolerogenic and immunogenic properties of NOD and B6.H2
g7 iNKT-conditioned DCs are abrogated by their respective treatment with
PD-L1– and CD70-blocking antibodies. A: DCs were puriﬁed from NOD and B6.H2
g7 mice treated with -GalCer and either anti–PD-L1 (400
g/mouse) or rIgG 24 h and 16 h previously and ﬁxed to prevent further maturation. DCs (2.5  10
4 per well) were then used to induce antigenic
mimotope-mediated proliferation of puriﬁed CFSE-labeled NOD.Rag1
null.AI4 T-cells (5  10
4 per well) after 3 days in culture. B: DCs were
puriﬁed from NOD and B6.H2
g7 mice treated with -GalCer 24 h previously and ﬁxed to prevent further maturation. DCs (2.5  10
4 per well) were
then used to induce antigenic mimotope-mediated proliferation of puriﬁed CFSE-labeled NOD.Rag1
null.AI4 T-cells (5  10
4 per well) in tissue
culture media containing 10 g/ml of anti-CD70 or rIgG. CFSE dilution of AI4 T-cells was assessed after 3 days in culture.
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B6.H2
g7 mice that had been pretreated with -GalCer or
vehicle. The recipients were also treated with a PD-L1–
blocking or control antibody simultaneously with and 2
days after AI4 T-cell infusion. PD-L1 blockade abrogated
the ability of -GalCer pretreatments to inhibit AI4 T-cell–
induced type 1 diabetes in NOD recipients (Fig. 6A). The
inability of iNKT-cell activation to inhibit AI4 T-cell–
mediated type 1 diabetes in B6.H2
g7 recipients was not
further inﬂuenced by PD-L1 blockade (Fig. 6B). Thus, the
ability of iNKT-cell activation to paradoxically induce
downstream type 1 diabetes–protective responses in NOD,
but not B6.H2
g7, mice is at least partly due to differing
activities of the T-cell–inhibitory PD-L1 molecule.
Differences in both iNKT-cells and DCs contribute to
their varying interactions in NOD and B6.H2
g7 mice.
Strain differences characterizing DCs, iNKT-cells, or both
could contribute to their differential interactions in NOD
and B6.H2
g7 mice. Hence, we initially determined whether
maturation responses of NOD and B6.H2
g (7) DCs varied
in a culture system where they were simultaneously ex-
posed to an equivalent pool of activated iNKT-cells. Equal
numbers of NOD and B6.H2
g7 splenocytes were cocul-
tured for 48 h in the presence or absence of -GalCer. In
the -GalCer–stimulated cultures, DCs from NOD mice
(CD45.1
) expressed reduced levels of CD86 (Fig. 7A) and
PD-L1 (Fig. 7B) compared with those of B6.H2
g7 origin
(CD45.2
), although each population had been exposed to
equivalent iNKT-derived signals. These results suggested
differences inherent to DCs from NOD versus B6.H2
g7
mice at least partially contribute to their variable re-
sponses to activated iNKT-cells.
The mixed splenocyte culture system described above
did not allow us to exclude the possibility that NOD versus
B6.H2
g (7) strain differences inherent to iNKT-cells also
contribute to variability in the downstream maturation
pattern of DCs. Furthermore, although the mixed spleno-
cyte experiment allowed for a matched pool of activated
iNKT-cells, it could not exclude the possibility that the
differential maturation patterns of NOD and B6.H2
g7 DCs
in this system were also dependent on contributions from
other interactive leukocyte populations. To address these
possibilities, puriﬁed iNKT-cells and DCs from each strain
were cultured together in a “crisscross” fashion in the
presence or absence of -GalCer. Under these conditions,
matched numbers of activated iNKT-cells isolated from
B6.H2
g7 mice had a greater capacity than those of NOD
origin to induce upregulation of CD86 and PD-L1 expres-
sion on DCs from both strains (Fig. 7C and D). Interest-
ingly, DC maturation responses in this assay system were
dependent solely on the strain of origin of the cocultured
iNKT-cells. Thus, NOD versus B6.H2
g7 strain differences
inherent to iNKT-cells contribute to their ability to induce
varying states of downstream DC maturation. Further-
more, these results, in conjunction with those from the
mixed splenocyte experiment described above, indicate
that in addition to activated iNKT-cells, contributions from
another leukocyte population(s) are required to induce
inherent differences in the subsequent maturation re-
sponses of DCs from NOD and B6.H2
g7 mice. The identi-
ﬁcation and functional characterization of this additional
leukocyte population(s) that inﬂuences whether iNKT-
conditioned DCs mature to a tolerogenic or immunogenic
state should be a fertile area of future investigation.
DISCUSSION
The present results verify the previously suggested, but
not deﬁnitively proven, mechanism that -GalCer–acti-
vated iNKT-cells at least partly protect NOD mice from
type 1 diabetes by driving the maturation of tolerogenic
DCs. In contrast, iNKT-conditioned DCs in B6.H2
g7 mice
mature to an alternative immunogenic state that supports
rather than inhibits AI4 T-cell–induced type 1 diabetes.
The downstream maturation of iNKT-conditioned DCs in
NOD and B6.H2
g7 mice to a tolerogenic versus an immu-
nogenic state is due to the induction of quantitatively
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FIG. 6. PD-L1 blockade abrogates -GalCer–mediated protection against AI4 T-cell–induced type 1 diabetes in NOD mice. Incidence of type 1
diabetes in recipient (A) NOD and (B) B6.H2
g7 (3–4 weeks old) female mice that were pretreated with -GalCer (2 g) or vehicle once weekly
for 4 weeks before being sublethally irradiated (600 R) and injected intravenously with 1  10
7 NOD.Rag1
null.AI4 splenocytes. Five days later,
the recipients received an additional dose of -GalCer or vehicle. Recipients were also injected intraperitoneally with PD-L1–blocking antibody
(M1H6; 250 g/mouse) or polyclonal rat IgG, at the same time as and 2 days after AI4 T-cell transfer.
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inhibitory molecules.
A series of T-cell costimulatory molecules were upregu-
lated to a much greater extent on iNKT-conditioned DCs
from B6.H2
g7 than NOD mice. In particular, CD70 and
OX40L expression levels were unchanged or strongly
upregulated on iNKT-conditioned DCs from NOD and
B6.H2
g7 mice, respectively. This could be signiﬁcant given
a report that iNKT-cells promote CD8
 cytotoxic T-cell
responses by inducing CD70 expression on DCs (30).
Indeed, without ruling out possible contributions from
other costimulatory molecules, CD70 blockade abrogated
the ability of iNKT-conditioned B6.H2
g7 DCs to support
diabetogenic AI4 T-cell activation.
Lower levels of costimulatory molecule expression on
NOD iNKT-conditioned DCs may explain why they do not
support type 1 diabetes development like those of B6.H2
g7
origin, but do not account for their disease-protective
capacity. An explanation for this protection appears to lie
in the observation that iNKT-cell–conditioned DCs also
upregulate expression of the T-cell–inhibitory PD-L1 mol-
ecule. Absolute levels of PD-L1 were higher on iNKT-
conditioned DCs from B6.H2
g7 than NOD mice. However,
PD-L1 blockade only marginally enhanced the already
strong ability of iNKT-conditioned B6.H2
g7 DCs to support
diabetogenic AI4 T-cell activation. In contrast, PD-L1
blockade signiﬁcantly enhanced the normally poor ability
of iNKT-conditioned NOD DCs to support AI4 T-cell
activation. PD-L1 blockade also abrogated the ability of
-GalCer–activated iNKT-cells to induce type 1 diabetes–
protective effects in NOD mice. These collective results
indicate the relative activity of inhibitory PD-L1 versus
various T-cell costimulatory molecules is greater in iNKT-
conditioned DCs in NOD than B6.H2
g7 mice.
The ﬁnding that PD-L1 expression plays an important
role in the type 1 diabetes–protective capacity of NOD
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FIG. 7. Differences inherent to NOD and B6.H2
g7 iNKT-cells and DCs contribute to their varying responses to iNKT-cell activation. MFI of (A)
CD86 and (B) PD-L1 antibody staining on CD11c
 DCs resident in mixed cultures of NOD and B6.H2
g7 splenocytes (n  3) incubated in the
presence or absence of -GalCer (200 ng/ml) for 48 h. The two populations of NOD and B6.H2
g7 DCs were distinguished from each other by
respective expression of the CD45.1 versus CD45.2 isoform. Boxed values indicate the within-strain fold change in CD86 and PD-L1 MFI on DCs
from -GalCer– compared with vehicle-treated splenocytes. Differences across strains in absolute expression levels of surface molecules and the
within-strain fold change induction above baseline between iNKT-conditioned NOD and B6.H2
g7 DCs were compared by one-way ANOVA. MFI of
(C) CD86 and (D) PD-L1 antibody staining on puriﬁed NOD and B6.H2
g7 DCs (1  10
5 per well) cultured with 1.5  10
4 syngeneic or allogeneic
iNKT-cells (n  3 for each cell type) in the presence of vehicle or -GalCer (200 ng/ml) for 18 h. Average MFI values of CD86 and PD-L1 antibody
binding between -GalCer–treated cultures with no common superscripts differed signiﬁcantly (P < 0.05) when analyzed by the Wilcoxon test
after one-way ANOVA.
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planation for our previous observation that such antigen-
presenting cells directly mediate the apoptotic deletion of
some AI4 T-cells (31). However, the ability of activated
iNKT-cells to inhibit type 1 diabetes development in NOD
mice is also at least partly Treg dependent (20). Tregs are
also reportedly less susceptible than conventional T-cells
to PD-1–mediated deletion (32). iNKT-conditioned DCs
from NOD and B6.H2
g7 mice maintain diabetogenic AI4
CD8 T-cells in a relatively quiescent and a highly activated
state, respectively. Hence, iNKT-conditioned DCs in NOD
mice may mediate PD-1–dependent apoptotic deletion of
at least some diabetogenic T-cells that become activated,
but keeping most of such effectors in a quiescent state also
allows them to be more easily suppressed by Tregs than in
the B6.H2
g7 strain. This latter possibility will be the
subject of future investigations.
In contrast to our current ﬁndings, it has been reported
that NOD mice must be pretreated with multiple, rather
than a single, injections of -GalCer to induce type 1
diabetes–protective tolerogenic DCs (33). However, this
study used a model system in which new diabetogenic
T-cells could be continuously generated from hematopoi-
etic precursors, whereas our studies evaluated the effects
of various iNKT-conditioned DC populations on a single
bolus of infused AI4 effectors.
Inferences for human type 1 diabetes intervention,
based upon the ability of iNKT-conditioned DCs from two
inbred mouse strains to differentially alter disease devel-
opment, must be drawn with caution. There is likely to be
comparable heterogeneity in iNKT-induced DC responses
in humans. Compared with those in other strains, NOD
DCs do not mature normally (34,35). This defect may be a
pathogenic component of autoimmunity, as NOD DCs
matured through ex vivo manipulation become type 1
diabetes protective (36). Similar DC maturation abnormal-
ities reportedly characterize some human type 1 diabetic
patients (37–39). If DCs from type 1 diabetic patients are
analogous to those of NOD mice, then iNKT-cell activation
may also restore their maturation to a tolerogenic state.
However, unlike the case in inbred mice, there is likely to
be more heterogeneity in the pathogenic basis of type 1
diabetes development in humans, including potential vari-
ability in DC functions. Such a scenario should preclude
consideration of iNKT-cell agonists as potential type 1
diabetes therapeutic agents until reliable biomarkers are
identiﬁed to predict how such compounds affect DC
maturation in individual patients.
Current data indicate that NOD versus B6.H2
g7 strain
differences inherent to iNKT-cells contribute to their vari-
able induction of downstream DC maturation responses.
NOD and B6.H2
g7 mice are further characterized by strain
differences inherent to DCs, but are also dependent on
contributions from another leukocyte population(s),
which underlies their variable iNKT-cell–induced matura-
tion patterns. NOD mice are reportedly characterized by
both iNKT-cell and DC anomalies (34,35,40–43). Treat-
ment with -GalCer may protect NOD mice from type 1
diabetes by compensating for both pathogenic iNKT-cell
and DC impairments. Conversely, B6.H2
g7 mice have
unimpaired iNKT-cells and DCs. This may account for why
in -GalCer–treated B6.H2
g7 mice, DCs mature to an
immunogenic rather than a tolerogenic state.
In summary, iNKT-conditioned DCs in NOD and B6.H2
g7
mice mature to a type 1 diabetes–protective or an immu-
nogenic disease-inducing state, respectively. These vary-
ing DC maturation states are characterized by differing
activity balances of T-cell–inhibitory and costimulatory
molecules. This heterogeneity of iNKT-cell and DC inter-
actions in inbred mouse strains raises concerns that
should be considered before trying to manipulate this axis
as a possible type 1 diabetes intervention approach in
genetically heterogeneous humans.
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